Treatment with Cardamonin reduces the secretion of IL-1β and TNF-α in patients with recurrent colitis and colitis-associated tumors and inhibits cell viability and the production of inflammatory cytokines in colorectal cancer cells in vitro. Here, IL1B is linked to colitis.